Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Cha... (arkets. Before Genitope Mr. Vuko wasexec...)

Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO

Date:9/8/2008

arkets. Before Genitope, Mr. Vuko was executive vice president and chief financial officer at Incyte Corporation, also a public company, which raised over $600 million during his tenure.

Beth Anne Piper, M.D., vice president, clinical development brings 19 years of clinical industry experience to Zosano. An endocrinologist by training, her most recent experience was as senior director of medical affairs and clinical development at FibroGen, where she drove the global development programs for their anemia portfolio. Ms. Piper also held positions at Pfizer and Bristol-Myers Squibb. Previously Ms. Piper worked at the Hospital for Special Surgery and New York Hospital, where she focused on metabolic bone and osteoporosis diseases.

Stephen Worsley, vice president, business development has held several senior licensing and business development positions in the biotechnology industry. Most recently, Mr. Worsley was vice president of business development at Raven biotechnology. Prior to Raven, he held senior business development positions at Abgenix and Tripos, Inc., and has successfully executed both licensing and joint venture agreements.

Zosano PTH patch is a novel transdermal patch formulation of parathyroid hormone (PTH) for the treatment of established osteoporosis. This product recently completed a Phase II program studying the Zosano transdermal patch formulation versus injectable Forteo in 165 women with severe osteoporosis in multiple sites across North and South America. Top line results from this study are expected to be available by the end of third quarter, 2008. Detailed results from the study have been submitted for presentation at an upcoming medical meeting in the fall.

About Zosano Pharma, Inc.

Zosano Pharma, Inc. is a privately held pharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications. Its lead clinical program is evaluating a parathyroid hormone (hPTH 1-
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
2. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
3. China Biopharma, Inc. Announces New Plan of Operation
4. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
5. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
6. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
7. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.

Post Your Comments:

Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Cha...(arkets. Before Genitope Mr. Vuko wasexec...)